Sheldon Koenig, Esperion CEO
Seeking 'financial flexibility,' Esperion sells European royalty on cholesterol-lowering drugs
Esperion has made another deal with a financial backer for an immediate cash haul in return for future revenue.
Esperion received $304.7 million from the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.